# Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

> **NCT05912062** · — · UNKNOWN · sponsor: **Institut Català d'Oncologia** · enrollment: 80 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab (neoadjuvant)
- **DRUG:** Pertuzumab (neoadjuvant)
- **DRUG:** Paclitaxel (neoadjuvant)

## Key facts

- **NCT ID:** NCT05912062
- **Lead sponsor:** Institut Català d'Oncologia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-22
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912062, "Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05912062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*